Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody-drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.
Reinheit:
98.5%
CAS Nummer:
[2376463-48-6]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten